

You have agreed to assist the French National Cancer Institute [henceforth, National Cancer Institute or INCa] in the fulfilment of its public service mission.

Out of respect for the general public and all of the professionals working alongside it, the National Cancer Institute is mindful of its impartiality and its independence of opinion. With this in mind, it is one of the INCa's duties to manage conflicts of interest in order to protect the credibility of experts, the public's trust in science and the scientific community and personal and institutional reputations. Transparency by all those involved is essential for accomplishing our public service mission in its entirety.

All experts must, prior to starting their mission, declare any connections they have that may cause a conflict of interests (e.g. the sale of company shares, abandonment of certain professional projects in competition) and commit themselves to respect the obligations and duties of the code of conduct and deontology annex to this form.

The form below must be used in this process.

The type of connections suggested relates to the most common situations and pick up on a number of objective and concrete criteria. Due to the specific nature of some situations, you must ensure that you examine and indicate if any other connections, past, present or future, may bias your judgment or give rise to suspicion of a conflict of interests between your assignments at INCa and your external activities.

Finally, over the course of your mission, it is your duty to withhold a judgment or refuse to participate in a decision if you reasonably consider that you cannot review the matter impartially or if you fear that your impartiality may be called into question.

Your declaration must be exhaustive, completed before any involvement in the work of INCa and must be updated at least once a year or whenever a change is made to the connections declared or a new conflict of interest arises. Failure to provide updates may lead to suspension of the assignment.

The method for evaluating the declarations and management of conflicts of interest is described in a document available on the National Cancer Institute website.

The information gathered below will be reproduced electronically and your declaration (apart from your contact details and information relating to your family members) will be published on the INCa website. In accordance with the French Data Protection Law No. 78-17 of 6 January 1978, modified in 2004, you have the right to access, correct and remove data relating to you held by INCa. You do have a right to oppose publication of your personal data only for legitimate reasons. If you wish to exercise this right and to be sent information relating to your person, please send your request by email to: bdd@institutcancer.fr or by post to the following address: National Cancer Institute, Plateforme Appels à Projets, 52 avenue André Morizet 92513 Boulogne Billancourt Cedex, France.

I, the undersigned:.....Judy Garber.....

- Undertake to meet the obligations and undertakings in the INCa code of conduct and deontology and in particular I undertake to keep confidential information given to me verbally, in writing or in any other form, particularly in carrying out expert work.
- declare upon my honour that to the best of my knowledge all interests, past, present and future, in a Company are listed below.
- undertake, in the event of modification of the interests above or acquisition of additional interests that must be brought to the INCa's attention, to notify INCa and immediately make a new public declaration of interests.

This declaration does not relieve me of my duty to mention again any interests I may have at the start of any expertise activity for INCa in which I am involved.

For acceptance:

Signature:

In this declaration:

- ❖ The term **Company** is defined as follows: a company (particularly within the health industry), a private or public professional organisation or an advisory organisation that falls within the scope of expertise or intervention of the National Cancer Institute. As the INCa is responsible for monitoring the World Health Organisation's Framework Convention on Tobacco Control, the tobacco industry is also covered.
- ❖ The term **Product** is defined as follows: a specific product or specific goods or services that fall within the scope of expertise or intervention of the National Cancer Institute.

1. Current financial interests in a company

None

Any financial interest in a Company (securities, listed or otherwise, whether these are shares, bonds or other financial assets in equity) must be declared.

Company	Type of investment (market values, shareholder's equity or bonds)	< €5,000 or < 5% of the capital	≥ €5,000 or ≥ 5% of the capital	Start date	End date

2. Activities performed on a personal basis

Activities involving research, scientific evaluation or consultancy for or on behalf of Companies must be declared. Where such activities relate to a Product, the name of the Product and the scope and the subject of the activity should be mentioned under the company name.

2.1 Long-term or permanent interests in a Company

As a director, employee, trustee, consultant, adviser, etc.

None

- Current, in negotiation or over the last 3 years

Company	Nature of activity / Subject / Product name	Payment	Start date	End date
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
NOVARTIS	Research/consulting (spouse)	<input checked="" type="radio"/> You/spouse <input type="radio"/> Institution <input type="radio"/> You/Institution	>10 yrs.	—
Pfizer	Research/consulting (spouse)	<input checked="" type="radio"/> You/spouse <input type="radio"/> Institution <input type="radio"/> You/Institution	>3 yrs	—
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		

2.2 Ad-hoc involvement: clinical and preclinical trials and scientific work

The activities referred to in this section involve participation in the performance of non-clinical and preclinical tests or studies (methodological studies, analytical tests, chemical, pharmaceutical, biological, pharmacological or toxicological tests, etc.), clinical trials and epidemiological studies, observational studies on practices and rules, etc.

As a principal investigator for a monocentric study, coordinating investigator or principal experimenter

None

- Current or over the last 3 years
- Involvement in carrying out the aforementioned trials or studies

Company	Nature of activities / Product name	Your role (principal investigator, coordinating investigator, principal experimenter, etc.)	Start date	End date
AstraZeneca	Olaparib	Principal Investigator	2008	2013

As a subinvestigator, secondary experimenter, contributor to the study

None

- Current or over the last 3 years
- Involvement in carrying out the aforementioned trials or studies

Company	Nature of activities / Product name	Your role (subinvestigator, secondary experimenter, contributor to the study, etc.)	Start date	End date
Numerous	Enroll medical trials (Co-investigator)	Numerous		

None

2.3 Ad-hoc involvement: expert reports or writing of promotional articles

- Current or over the last 3 years

Company	Scope of the expert's report / Subject / Product name	Payment	Start date	End date
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution		

2.4 Ad-hoc involvement: consultancy work

None

- Current or over the last 3 years
- Ad-hoc consultant, participation in a working group, a think tank or an audit within the context of a professional accreditation body, etc.

Company	Nature of the service or subject / Product name	Payment	Number of days/year	Start date	End date
Generations Health	Pharmacogenetics	<input type="radio"/> None <input checked="" type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution	2	2010	2012
Novartis	mechanisms of hormone action in cancer	<input type="radio"/> None <input checked="" type="radio"/> You /Spouse <input type="radio"/> Institution <input type="radio"/> You/Institution	5	1995	-
Pfizer	mechanisms of hormone action in cancer	<input type="radio"/> None <input checked="" type="radio"/> You /spouse <input type="radio"/> Institution <input type="radio"/> You/Institution	3	2003	-

2.5 Ad-hoc involvement: conventions, conferences, symposia, other meetings

- Meetings with financial backing from or organised by a Company that manufactures or sells a Product

Invitations as a participant

- Current or over the last 3 years

None

Company	Place and title of meeting / Subject / Product name	Payment	Date
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution	
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution	
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution	
		<input type="radio"/> None <input type="radio"/> You <input type="radio"/> Institution <input type="radio"/> You/Institution	

Invitations as an auditor (travel and accommodation paid for by a Company)

- Current or over the last year

None

Company	Place and title of meeting / Subject / Product name	Date

None

2.6 Ad-hoc involvement: other

* None

- **Holder of the patent** for or inventor of a Product, process or other form of intellectual property, party or witness to a procedure relating to a Product

Company	Nature of activity / Product name	Start date	End date

3. Substantial payments made by a Company to the budget of an institution/department for which you are responsible

None

- Current or over the last 3 years
- Individuals responsible for research organisations, institutes, departments, services, research associations, patient associations, etc. are covered in this section.

Company	Reason for payment	Beneficiary	% of institution's budget	Start date	End date
Novartis	Research support (basic)	Spouse research at Dana-Farber	<1%	1995	-
Pfizer	Research support (basic)	Cancer Institute	4%	2003	-

4. Other interests (financial or otherwise) connected to your assignments for the INCa

None

- Other facts or interests that could be considered as detrimental to your impartiality
- Other facts that you feel should be brought to the attention of the National Cancer Institute
- e.g. personal involvement or involvement of a family member in a specific research project

Company (where applicable)	Nature of activity	Remarks	Start date	End date